FRESH TRACKS THERAPEUTICS IN (FRTX) Stock Price & Overview
NASDAQ:FRTX • US10802T2042
Current stock price
The current stock price of FRTX is 0.79 USD. Today FRTX is down by -2.48%. In the past month the price decreased by -4.76%. In the past year, price decreased by -42.75%.
FRTX Key Statistics
- Market Cap
- 4.716M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.67
- Dividend Yield
- N/A
FRTX Stock Performance
FRTX Stock Chart
FRTX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to FRTX. When comparing the yearly performance of all stocks, FRTX is a bad performer in the overall market: 89.63% of all stocks are doing better.
FRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FRTX. FRTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
FRTX Earnings
FRTX Forecast & Estimates
7 analysts have analysed FRTX and the average price target is 4.59 USD. This implies a price increase of 481.01% is expected in the next year compared to the current price of 0.79.
For the next year, analysts expect an EPS growth of 5.44% and a revenue growth -58.02% for FRTX
FRTX Groups
Sector & Classification
FRTX Financial Highlights
Over the last trailing twelve months FRTX reported a non-GAAP Earnings per Share(EPS) of -2.67. The EPS increased by 68.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -68.63% | ||
| ROE | -82.48% | ||
| Debt/Equity | 0 |
FRTX Ownership
FRTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 351.47B | ||
| AMGN | AMGEN INC | 15.09 | 185.95B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 161.855B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 109.449B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 79.456B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 40.768B | ||
| INSM | INSMED INC | N/A | 29.176B | ||
| NTRA | NATERA INC | N/A | 28.878B | ||
| BIIB | BIOGEN INC | 11.44 | 27.06B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.812B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 24.859B | ||
| MRNA | MODERNA INC | N/A | 20.119B | ||
| INCY | INCYTE CORP | 12.23 | 18.836B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FRTX
Company Profile
Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 13 full-time employees. The firm is engaged in transforming patient lives through the development of differentiated prescription therapeutics. Its pipeline is focused on providing existing treatment paradigms and features several new chemical entities that inhibit novel targets with potential for autoimmune, inflammatory, and other debilitating diseases. The Company’s strategy is exploring therapies by identifying, pursuing, and developing therapeutics that can help people struggling with autoimmune, inflammatory, and other debilitating diseases. Its pipeline includes FRTX-02, FRTX-10, Next-Generation Kinase Inhibitors and FRTX-03. FRTX-02 is a potential Oral DYRK1A Inhibitor for the treatment of autoimmune and inflammatory diseases. Its FRTX-10 is a covalent Stimulator of Interferon Genes (STING) inhibitor candidate for the potential treatment of autoimmune, inflammatory, and rare genetic diseases.
Company Info
IPO: 1993-03-10
FRESH TRACKS THERAPEUTICS IN
5777 Central Ave Ste 102
Boulder COLORADO US
Employees: 13
Phone: 17205054755
FRESH TRACKS THERAPEUTICS IN / FRTX FAQ
Can you describe the business of FRESH TRACKS THERAPEUTICS IN?
Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 13 full-time employees. The firm is engaged in transforming patient lives through the development of differentiated prescription therapeutics. Its pipeline is focused on providing existing treatment paradigms and features several new chemical entities that inhibit novel targets with potential for autoimmune, inflammatory, and other debilitating diseases. The Company’s strategy is exploring therapies by identifying, pursuing, and developing therapeutics that can help people struggling with autoimmune, inflammatory, and other debilitating diseases. Its pipeline includes FRTX-02, FRTX-10, Next-Generation Kinase Inhibitors and FRTX-03. FRTX-02 is a potential Oral DYRK1A Inhibitor for the treatment of autoimmune and inflammatory diseases. Its FRTX-10 is a covalent Stimulator of Interferon Genes (STING) inhibitor candidate for the potential treatment of autoimmune, inflammatory, and rare genetic diseases.
Can you provide the latest stock price for FRESH TRACKS THERAPEUTICS IN?
The current stock price of FRTX is 0.79 USD. The price decreased by -2.48% in the last trading session.
Does FRESH TRACKS THERAPEUTICS IN pay dividends?
FRTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of FRTX stock?
FRTX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists FRTX stock?
FRTX stock is listed on the Nasdaq exchange.
Is FRESH TRACKS THERAPEUTICS IN (FRTX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FRTX.
Who owns FRESH TRACKS THERAPEUTICS IN?
You can find the ownership structure of FRESH TRACKS THERAPEUTICS IN (FRTX) on the Ownership tab.